| Summary: | Chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by progressive, partially reversible airway obstruction and lung hyperinflation; systemic manifestations; and increasing frequency and severity of exacerbations. Pathological changes in the lung vary between individuals but usually involve a combination of airway inflammation (chronic bronchitis) and parenchymal destruction (emphysema). Bronchodilator therapy with short- or long-acting inhaled beta-2 agonists (SABAs, LABAs) or muscarinic antagonists (SAMAs, LAMAs) is a mainstay of COPD therapy. Aclidinium bromide (ACL) (Tudorza Genuair) is an inhaled LAMA indicated for long-term maintenance bronchodilator treatment in patients with COPD, including chronic bronchitis and emphysema. In Canada, ACL is available in a pre-loaded, multi-dose dry powder inhaler that is used to deliver the recommended dose (400 mcg twice daily by oral inhalation). The objective of the review was to evaluate the beneficial and harmful effects of ACL in adult patients with moderate to severe COPD.
|
|---|